Erratum: Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer (Clinical and Translational Oncology DOI: 10.1007/s12094-008-0254-7);Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer

Clinical and Translational Oncology

Volumn 10, Issue 9, 2008, Pages 583-586

  García, José Miguel Jurado ^a   Sánchez, Alfonso ^a   Pajares, Bella ^a   Pérez, Elisabeth ^a   Alonso, Lorenzo ^a   Alba, Emilio ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

Author keywords

Bevacizumab; Metronomic cyclophosphamide; Ovarian cancer; Platinum resistant

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CYCLOPHOSPHAMIDE; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ADULT; AGED; ARTICLE; CYSTADENOCARCINOMA; DRUG RESISTANCE; FEMALE; HUMAN; METASTASIS; MIDDLE AGED; ORAL DRUG ADMINISTRATION; OVARY TUMOR; PATHOLOGY; RETROSPECTIVE STUDY; SALVAGE THERAPY; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; CYSTADENOCARCINOMA, SEROUS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 56149111692     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-008-0254-7     Document Type: Erratum

References (29)

1. Jemal A, Siegel R, Ward E et al (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43-66
2. Ozols R, Bundy B, Creer B et al (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 17:3194-3200
3. Gordon AN, Fleagle JT, Guthrie D et al (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III trial of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19:3312-3322
4. Ozols RF (2001) The current role of gemcitabine in ovarian cancer. Semin Oncol 28:18-24
5. Markman M, Hall J, Spitz D et al (2002) Phase II trial of weekly single agent paclitaxel in platinum/ paclitaxel refractory ovarian cancer. J Clin Oncol 20:2365-2369
6. Burguer RA, DiSaia PJ, Roberts JA et al (1999) Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer. Gynecol Oncol 72:148-153
7. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70
8. Brahimi-Horn C, Berra E, Pouysségur J (2001) Hypoxia: the tumor's gateway to progression along the angiogenic pathway. Trends Cell Biol 11:S32-S36
9. Dvorak HF (2002) Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20: 4368
10. Yamamoto S, Konishi I, Mandai M et al (1997) Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer 76:1221-1227
11. Hartenbach EM, Olson TA, Goswitz JJ et al (1997) Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. Cancer Lett 121:169-175
12. Shen GH, Ghazizadeh M, Kawanami O et al (2000) Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer 83:196-203
13. Ferrara N, Hillan KJ, Novotny W et al (2005) Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333:328-335
14. Hu L, Hofmann J, Holash J et al (2005) Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin Cancer Res 11:6966-6971
15. Kerbel RS (1991) Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 13: 31-36
16. Kerbel RS, Viloria-Petit A, Klement G et al (2000) Accidental anti-angiogenic drugs: antioncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur J Cancer 36:1248-1257
17. Bello L, Carrabba G, Giussani C et al (2001) Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res 61:7501-7506
18. Man S, Bocci G, Francia G et al (2002) Antitumor effects in mice of low dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 62:2731-2735
19. Burstein HJ, Spiegel D, Kindsvogel K et al (2005) Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: a randomized phase II study. Breast Cancer Res Treat 92:1s [suppl abstr 4
20. Burguer RA, Sill M, Monk B et al (2007) Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer: a Gynecologic Oncology Group (GOG) study. J Clin Oncol 25:5165-5171
21. Cannistra SA, Matulonis UA, Penson RT et al (2007) Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25:5180-5186
22. Garcia AA, Hirte H, Fleming G et al (2008) Phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian cancer (OC): a Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia. J Clin Oncol 26:76-82
23. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
24. Rustin GJ, Marples M, Nelstrop AE et al (2001) Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol 19:4054-4057
25. Rustin GJ (2003) Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol 21[10 Suppl]:187-193
26. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluoracil and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342
27. Wright JD, Hagemann A, Rader JS et al (2006) Bevacizumab combination therapy in recurrent, platinum-refractory epithelial ovarian carcinoma. Cancer 107:83-89
28. Koner JA, Fallon K, Pezulli S et al (2007) A phase II study of intravenous (IV) and intraperitoneal (IP) paclitaxel (Tax), IP cisplatin (Cis) and IV bevazicumab (Bev) as first-line chemotherapy for optimal stage II or III ovarian, primary peritoneal, and fallopian tube cancer. J Clin Oncol 25[Suppl] [Abstract 5523
29. Burguer RA (2007) Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol 25:2902-2908